Muhsen Issa

Cancer Risk in Kidney Transplant Recipients on Belatacept Versus Calcineurin Inhibitors: A Systematic Review and Meta-Analysis

BACKGROUND: Belatacept has been increasingly used as a maintenance immunosuppression in kidney transplant recipients since its approval in 2011, due to favorable renal and cardiovascular profiles compared with calcineurin inhibitors (CNIs). However, the long-term risk of cancers...